Biotech company Immutep
(ASX:IMM) says the first patient has been dosed with the combination of Keytruda® and efti for TACTI-002, a Phase II clinical study.
The study will evaluate the combination of Immutep’s lead product candidate eftilagimod alpha (“efti” or “IMP321”) with Merck and Cos KEYTRUDA® or pembro, a PD-1 blocking antibody, in up to 109 patients.
The patients have second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.
The study will take place in up to 13 study centres across the U.S., Europe and Australia.
Recruitment for the trial commenced at 2 sites in Australia, 1 site in the US, 4 sites in Europe.
Initial data from their TACTI-mel Phase 1 study in melanoma has shown that the combo is delivering long lasting and durable responses.
Shares in Immutep
(ASX:IMM) closed 2.94 per cent higher to 3.5 cents.
